Aerovance Inc. announced it has completed patient enrollment in a Phase 2b clinical trial of the inhaled dry powder formulation of Aerovant for the treatment of uncontrolled asthma. Top-line results are expected by the second quarter of 2010. Named AeroTrial(TM), the study enrolled approximately 540 patients at 75 sites in the United States and Europe.
FULL STORY

Source: Pharma Industry / Biotech Industry News From Medical News Today